CRISIL Ltd. Downgraded to Hold by MarketsMOJO Amid Valuation and Technical Concerns

Quality Assessment: Strong Fundamentals but Moderate Growth

CRISIL maintains a robust quality profile, underpinned by high management efficiency and a net-debt-free balance sheet. The company reported a return on equity (ROE) of 27.03% in its latest financials, with a return on capital employed (ROCE) of 40.16%, signalling effective utilisation of capital and strong profitability. The first quarter of FY26-27 saw net sales rise by 27.56% to ₹1,075.39 crores, while profit before tax (PBT) excluding other income grew 28.43% to ₹258.70 crores. Net profit after tax (PAT) also increased by 26.2% to ₹216.46 crores, reflecting operational strength.

However, the company’s long-term growth trajectory appears moderate, with net sales expanding at an annualised rate of 14.40% over the past five years. This growth rate, while respectable, is less aggressive compared to some peers in the capital markets ratings industry. Despite this, CRISIL’s consistent profitability and efficient capital management continue to support its quality grade, which remains stable.

Valuation: Elevated Metrics Prompt Caution

The most significant factor influencing the downgrade is CRISIL’s valuation, which has shifted from expensive to very expensive. The stock currently trades at a price-to-earnings (PE) ratio of 38.41, considerably higher than industry peers such as CARE Ratings (PE of 27.73) and ICRA (PE of 21.14). The price-to-book value stands at 10.38, indicating a premium valuation relative to the company’s net assets.

Enterprise value (EV) multiples further highlight the stretched valuation: EV to EBIT is 30.91, EV to EBITDA is 27.16, and EV to capital employed is 12.41. The PEG ratio of 1.78 suggests that while earnings growth is factored into the price, the premium remains substantial. Dividend yield is modest at 1.36%, which may not sufficiently compensate investors for the elevated price levels.

Given these metrics, the stock is considered very expensive, which has led analysts to adopt a more cautious stance despite the company’s strong fundamentals.

Financial Trend: Positive Quarterly Performance Amid Mixed Long-Term Returns

CRISIL’s recent quarterly results reinforce its financial strength, with double-digit growth in sales and profits. The company’s net sales for Q1 FY26-27 grew 27.56%, PBT excluding other income rose 28.43%, and PAT increased by 26.2%. These figures reflect operational resilience and effective cost management.

However, the stock’s price performance relative to the broader market presents a mixed picture. Year-to-date (YTD), CRISIL has delivered a 7.49% return, outperforming the Sensex, which declined by 14.61% over the same period. Over one year, the stock’s return is a modest 0.30%, compared to the Sensex’s negative 9.52%. Longer-term returns are more favourable, with five-year gains of 70.73% versus the Sensex’s 21.96%, and a ten-year return of 111.45%, though this trails the Sensex’s 157.21% appreciation.

These trends suggest that while CRISIL has demonstrated solid financial growth and outperformance in the short to medium term, its long-term capital appreciation has been somewhat subdued relative to the benchmark index.

Technical Analysis: Shift to Mildly Bullish Signals

The technical outlook for CRISIL has shifted from bullish to mildly bullish, contributing to the revised investment rating. Weekly technical indicators such as the Moving Average Convergence Divergence (MACD) and Bollinger Bands remain bullish, while monthly MACD and Know Sure Thing (KST) indicators have turned bearish. The Relative Strength Index (RSI) shows no clear signal on both weekly and monthly charts.

Moving averages on the daily chart continue to support a bullish stance, but the Dow Theory presents a mixed view with weekly mildly bearish and monthly mildly bullish signals. On-balance volume (OBV) is neutral on a weekly basis but bullish monthly, indicating some accumulation over the longer term.

Overall, the technical picture is less decisive than before, reflecting a cautious market sentiment that aligns with the Hold rating. The stock’s recent trading range between ₹4,450.60 and ₹4,705.00, with a current price near ₹4,649.20, suggests consolidation near its 52-week high of ₹5,060.00.

Comparative Industry Position and Market Capitalisation

CRISIL operates within the capital markets ratings industry, where valuation multiples vary significantly among peers. Compared to CARE Ratings and ICRA, CRISIL’s valuation is the highest, reflecting investor confidence in its brand and market position but also signalling potential overvaluation risks. The company is classified as a small-cap stock, which may contribute to higher volatility and sensitivity to market sentiment.

Its Mojo Score stands at 64.0, with a Mojo Grade downgraded to Hold from Buy, reflecting the combined impact of valuation concerns and technical uncertainties despite solid financials. This score aligns with a cautious investment stance, advising investors to monitor developments closely before committing additional capital.

Conclusion: Hold Rating Reflects Balanced View

CRISIL Ltd.’s downgrade from Buy to Hold is a measured response to evolving market conditions and company-specific factors. The firm’s strong financial performance, high management efficiency, and net-debt-free status underpin its quality credentials. However, the very expensive valuation metrics and mixed technical signals have introduced caution into the investment thesis.

Investors should weigh the company’s solid fundamentals against the premium price and subdued long-term growth prospects. While short-term returns have outpaced the Sensex, the stock’s modest one-year performance and technical indicators suggest limited upside momentum currently. As such, a Hold rating is appropriate, signalling that existing shareholders may retain positions but new investors should await clearer signals or valuation corrections.

Continued monitoring of quarterly results, valuation trends, and technical developments will be essential to reassess CRISIL’s investment potential in the coming months.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today